11210 research outputs found
Sort by
Downstream Testing Following Coronary Computed Tomography Angiography: A Decade of Clinical Practice (2012–2022)
No full textAssessment of Fosaprepitant and Aprepitant Use as an Independent Risk Factor for Ifosfamide Neurotoxicity
No full textInfluence of Microvascular Fluorescence Angiography in the Deliberations of the Hyperbaric and Wound Care Physician
No full textRetrospective Cohort Study of Microvascular Fluorescence Angiography (MFA) Use in Hyperbaric Oxygen Therapy Patients Following Lower Extremity Amputation Complicated by Flap Ischemia
No full text
Clinical Insights and Case Analysis of Disorders Attributed to Cicadas in the Emergency Department (CICADA)
No full textIgA nephropathy: An overview of the clinical trials
No full textIgA nephropathy (IgAN) is characterized by the deposition of poorly-O-galactosylated IgA1 (also referred to as galactose-deficient IgA1 or gd-IgA1) containing immune complexes in the glomerular mesangium. This triggers a variable degree of glomerular inflammation that leads to progressive kidney damage and often kidney failure. The acceptance of proteinuria reduction as a reasonably likely surrogate end point for treatment effects on progression to kidney failure has led to many clinical trials evaluating novel and repurposed therapies for IgAN. New treatments leverage different aspects of IgAN pathophysiology, including the modulation of mucosal immunity, mechanisms of B-cell activation, and complement activity. The approval of the first treatments evaluated specifically for IgAN (including delayed-release budesonide, sparsentan, atrasentan, and iptacopan) represent meaningful advancements in the management landscape, and promisingly, many more treatments seem poised to arrive. This review compiles a list of current active trials for IgAN and highlights the necessity for ongoing research to optimize therapeutic strategies to further improve outcomes for those living with IgAN
Human Ecology, 1969 Fall, V1 N1
No full textLutheran General Hospital, Park Ridge, IL: Magazine published quarterly by the Lutheran General and Deaconess Hospitals. This is the inaugural issue and keeps employees and friends of the hospital informed on current news and hospital updates.https://institutionalrepository.aah.org/alldocuments/2220/thumbnail.jp
Human Ecology, 1974 Spring-Summer, V5 N2
No full textLutheran General Hospital, Park Ridge, IL: Magazine published quarterly by the Lutheran General and Deaconess Hospitals. This publication keeps employees and friends of the hospital informed on current news and hospital updates.https://institutionalrepository.aah.org/alldocuments/2225/thumbnail.jp
The medical community must not remain silent about healthcare and water access denial in Palestine
No full textPhysicians have a duty to oppose the human suffering and human rights abuses occurring in Gaza, particularly the violations of international humanitarian law (IHL). We especially call attention to the scarcity of potable water in Gaza, which has fueled outbreaks of hepatitis A, polio, and skin infections and has created a public health crisis that is further exacerbated by the destruction of healthcare infrastructure and targeting of healthcare workers. The time is long overdue for physicians to affirm that IHL, including guaranteed access to healthcare and potable water, must be upheld to protect the health and safety of all Palestinians. Moreover, as violence against Palestinians and mass displacement campaigns are escalating in the West Bank, this is a pivotal moment for action to prevent further harms